PSA密度预测主动监测中MRI阴性前列腺癌患者的Gleason升级
本研究纳入98例低危或有利中危前列腺癌且基线或监测mpMRI阴性(无PI-RADS≥2病灶)的主动监测患者,评估PSA、前列腺体积和PSAD预测确诊活检Gleason升级的能力。
要点
- MRI阴性主动监测患者中PSAD可区分确诊活检Gleason升级风险。
- PSAD截断值0.08对病理升级的阴性预测值为98%。
核心结论
- PSAD能可靠区分MRI阴性低级别前列腺癌主动监测患者确诊活检Gleason升级风险。
- PSAD可用于临床降低部分患者的监测强度。
研究设计与样本
- 分析限制于初始活检GG1且基线或监测mpMRI阴性(无PI-RADS≥2病灶)的患者,共98例。
主要发现
- 98例中14例(14.3%)在确诊活检时发生Gleason升级。
- PSAD截断值0.08对病理升级的阴性预测值为98%。
关键数值与推荐
- PSAD截断值0.08对病理升级的阴性预测值为98%。
临床怎么用
- 对MRI阴性的低级别前列腺癌主动监测患者,可用PSAD评估Gleason升级风险。
- PSAD较低的患者或可考虑降低监测强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether PSA density (PSAD), can sub-stratify risk of biopsy upgrade among men on active surveillance (AS) with normal baseline MRI. METHODS: We identified a cohort of patients with low and favorable intermediate-risk prostate cancer on AS at two large academic centers from February 2013 - December 2017. Analysis was restricted to patients with GG1 cancer on initial biopsy and a negative baseline or surveillance mpMRI, defined by the absence of PI-RADS 2 or greater lesions. We assessed ability of PSA, prostate volume and PSAD to predict upgrading on confirmatory biopsy. RESULTS: We identified 98 patients on AS with negative baseline or surveillance mpMRI. Median PSA at diagnosis was 5.8 ng/mL and median PSAD was 0.08 ng/mL/mL. Fourteen men (14.3%) experienced Gleason upgrade at confirmatory biopsy. Patients who were upgraded had higher PSA (7.9 vs 5.4 ng/mL, P = .04), PSAD (0.20 vs 0.07 ng/mL/mL, P < .001), and lower prostate volumes (42.5 vs 65.8 mL, P = .01). On multivariate analysis, PSAD was associated with pathologic upgrade (OR 2.23 per 0.1-increase, P = .007). A PSAD cutoff at 0.08 generated a NPV of 98% for detection of pathologic upgrade. CONCLUSION: PSAD reliably discriminated the risk of Gleason upgrade at confirmatory biopsy among men with low-grade prostate cancer with negative MRI. PSAD could be clinically implemented to reduce the intensity of surveillance for a subset of patients.
引用
- Press BH, Khajir G, Ghabili K, et al. Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI. Urology. 2021. PMID: 34087311. doi:10.1016/j.urology.2021.05.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。